Lipocine INC 10-Q quarterly reports

Lipocine Inc. (LPCN) filed its Form 10-Q for the quarter ended June 30, 2026, detailing ongoing development efforts, licensing agreements, and financial performance, including a significant setback in its LPCN 1154 Phase 3 trial for postpartum depression.

Lipocine Inc. reported Q1 2026 results, highlighting a significant setback in its LPCN 1154 Phase 3 trial for postpartum depression, while continuing to advance other pipeline candidates and manage existing licensing agreements.

Lipocine Inc. reported a significant increase in net loss for Q3 and the nine months ended September 30, 2025, driven by higher R&D expenses for its CNS pipeline, despite new licensing agreements for TLANDO.

Lipocine Inc. reported a reduced net loss for Q2 2025 compared to the prior year, driven by increased license and royalty revenues, while advancing multiple clinical programs and securing new international TLANDO licenses.

Lipocine Inc. announces its financial results for the first quarter of 2025, highlighting royalty revenue of $94,000 and ongoing development of its pipeline candidates.

Lipocine Inc. announced its financial results for the third quarter of 2024, highlighting progress in its clinical programs and licensing agreements.

Lipocine Inc. announced its second quarter 2024 financial results, highlighting a significant licensing revenue increase and progress in its clinical programs.

Lipocine Inc. reported a profitable first quarter of 2024, primarily driven by a significant licensing agreement.